In the total HR+/HER2− BC population, the performance of axillary lymph node dissections (ALNDs) decreased from 26% in 2011-2013 to 9% in 2017-2019 (Supplementary Table S2, available at https://doi.org/10.1016/j.esmoop.2024.103008). The gene discussed is HR; the disease is breast cancer.